A heated debate over e-cigarettes, heated tobacco and nicotine pouches is playing out in Geneva, where more than 1,400 delegates have convened to review the World Health Organization’s tobacco control treaty and strategies to confront the global tobacco epidemic. The central question: can non-combustible nicotine products help established smokers quit, or do they create new public-health harms?
Proponents of harm reduction say these products are not harmless but are likely much less dangerous than combustible cigarettes, which remain responsible for the bulk of tobacco-related deaths. Their argument is pragmatic: for people who cannot or will not stop using nicotine, offering alternatives that avoid burning tobacco could reduce exposure to the toxins produced by combustion and save lives. Prominent advocates include former WHO treaty architect Dr. Derek Yach, who says the simple ‘‘quit or die’’ framing overlooks the complexity of nicotine dependence. Supporters also point to policies in places such as the U.K., where the National Health Service endorses e-cigarettes as a tool to help smokers stop. Independent researchers urge open scientific debate and more funding for studies on how these products might be used responsibly for cessation.
Opponents, however, warn of real dangers. WHO leaders have taken a firm position against promoting e-cigarettes as a cessation aid, calling for strict regulation and arguing that the tobacco industry has co-opted ‘‘harm-reduction’’ language to market new products. Officials cite rising youth use: recent estimates suggest about 15 million children worldwide are now using e-cigarettes, with youth uptake growing faster than adult use. Critics also raise concerns about flavors and packaging that appeal to young people, and about an industry with a long record of misleading claims now profiting from novel nicotine products.
Public-health groups and pediatric experts point to emerging evidence associating e-cigarette use with cardiovascular, metabolic, respiratory and oral health problems, and possibly cancer. They note that many users combine vaping with smoking, and some research suggests dual users may face higher risks than those who smoke only. Scientific uncertainty also exists about product-specific hazards, such as exposure to metals from heating elements and other contaminants; studies have produced mixed results, and long-term risks will take time to characterize.
Skepticism about the motives and tactics of tobacco companies is widespread. Critics recall past marketing strategies—such as ‘‘low-tar’’ claims—that created a false impression of safety while profits continued. Some former public-health officials view current industry-sponsored harm-reduction efforts warily, arguing they could distract from proven tobacco-control measures and potentially rekindle nicotine addiction among a new generation.
Defenders of harm-reduction contend that industry involvement should not automatically rule out the potential public-health contribution of non-combustible nicotine products. They call for policies grounded in evidence rather than ideology, including regulation that restricts youth access and marketing while permitting adult smokers access to less harmful alternatives. Many on both sides also agree that product quality and variation make blanket judgments difficult and that strong regulatory standards are needed.
What unites nearly everyone at the Geneva talks is the high stakes. With roughly 1.2 billion tobacco users worldwide, most in low- and middle-income countries, regulatory choices about cessation tools, youth protections and market access will influence the trajectory of the tobacco epidemic for decades. The debate now is whether the next phase of tobacco control will incorporate regulated harm-reduction strategies, reject them outright, or seek a middle path that maximizes quitting opportunities while minimizing youth initiation and long-term harms.